Elite in Hemoglobinopathy

Paul T. Telfer

London, ENG, GB 
Elite in Hemoglobinopathy
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Paul Telfer practices in London, United Kingdom. Mr. Telfer is rated as an Elite expert by MediFind in the treatment of Hemoglobinopathy. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Gastrostomy.

His clinical research consists of co-authoring 61 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 57 articles and participated in 3 clinical trials in the study of Hemoglobinopathy.

Gender
Male

Locations

London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Enrollment Status: Terminated
Publish Date: June 13, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 3
A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients With Sickle Cell Disease
A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients With Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 2
View 2 Less Clinical Trials

61 Total Publications

Can health inequalities in sickle cell disease be addressed through novel therapies?
Can health inequalities in sickle cell disease be addressed through novel therapies?
Journal: HemaSphere
Published: May 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Telfer's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile